Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of PEP and EUFLEXXA in Knee Osteoarthritis
NCT06463132Phase 1Not yet recruiting
- Sponsor
- RION
- Start
- Nov 2024
- Primary completion
- Nov 2025
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of platelet-derived exosome product in knee osteoarthritis (OA) (4 arms), sponsored by RION. Primary endpoint: Occurrence of Dose-Limiting Toxicities at 90 days. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
platelet-derived exosome product
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06463132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06463132.